Vamsidhar Velcheti

Vamsidhar Velcheti is a thoracic oncologist who has contributed to clinical investigation of anti-LAG3 checkpoint inhibitor combinations, including studies of relatlimab plus nivolumab in thoracic malignancies following the FDA approval of the combination in melanoma based on RELATIVITY-047. He has contributed to biomarker analyses identifying LAG3 expression thresholds and immune gene signatures that correlate with dual checkpoint inhibitor response. He leads multiple IO combination trials in NSCLC and has been an advocate for next-generation checkpoint inhibitor development.